Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, PDT, PLW

Amnio Technology Awarded U.S. Patent for Amniotic Allografts


PHOENIX, Sept. 23, 2021 /PRNewswire/ -- Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that the United States Patent and Trademark Office has issued a new patent titled, "Enriched Multilayer Amnion Derived Tissue Graft." The new patent strengthens Amnio Technology's intellectual property position by further protecting its advanced allograft manufacturing processes in the United States. 

Amnio Technology Awarded U.S. Patent for Amniotic Allografts

"This newest patent issuance highlights the investments Amnio Technology has made in the areas of human tissue-based product manufacturing excellence and clinical utility" said Senior Director of New Product Development, Rob Diller, PhD. "The fact that we are able to protect the intellectual property of our continued allograft research speaks to the high caliber of our research team."

Amnio Technology holds a total of five U.S.-issued patents. The Company's intellectual property is also protected in the European Union by the patent, "Acellular Amnion Derived Therapeutic Compositions," issued this year.

William Brown, Managing Director of Operations, echoed Dr. Diller's sentiment, "Through the dedicated and purposeful work of our Scientific and Research Teams, Amnio Technology continues to develop and provide products that improve patient quality of life. We are pleased that our advancements in regenerative medicine are continuously recognized by the United States Patent and Trademark Office and its international counterparts."  

About Amnio Technology

Amnio Technology is a clinical stage biotechnology company dedicated to advancing the science of regenerative medicine. Established in 2013, Amnio Technology has developed core competencies in Good Tissue Practice and HCT/P Safety becoming a global leader in the development and distribution of amniotic tissue allografts. The Company has a robust pipeline of products and its liquid allograft for the treatment of chronic ulcers, PalinGen® Flow, is currently in a Phase 2 clinical trial. For more information about Amnio Technology, please visit the Company website at www.amniotechnology.com.

SOURCE Amnio Technology


These press releases may also interest you

at 11:45
SummaryProduct: Henna cones Issue: Chemical hazard / Product safety What to do: Stop using and selling them immediately and dispose of them in regular household garbage Who this is for: General public / Industry; Retail, Importers IssueHealth Canada...

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...



News published on and distributed by: